Foxo technologies completes strategic alternatives review and outlines latest progress executing corporate strategy

Minneapolis--(business wire)--foxo technologies inc. (nyse american: foxo) (“foxo” or the “company”), a leader in the field of commercializing epigenetic biomarker technology, today announces it has completed its strategic review, following recent management changes, and provided a business update on the company's progress and plans. mark white, interim ceo of foxo technologies, stated, “since taking the helm just over a month ago, foxo's new management team has initiated a significant restruct.
FOXO Ratings Summary
FOXO Quant Ranking